In ESTEEM® 1
33% PASI-75 response with Otezla 30 mg
twice daily (n = 562)
vs 5% with placebo (n = 282) at week 16
(primary endpoint; P < 0.0001)
In PALACE™ 1
38% ACR20 response with Otezla 30 mg
twice daily (n = 168)
vs 19% with placebo (n = 168) at week 16
(primary endpoint; P = 0.0001)
ACR, American College of Rheumatology; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; PASI, Psoriasis Area and Severity Index.
References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation. 2. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49. 3. Paul C, Cather J, Gooderham M, et al. Br J Dermatol. 2015;173(6):1387-1399. 4. Data on file, Celgene Corporation. 5. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. J Rheumatol. 2015;42(3):479-488.
Indications & Important Safety Information
Please click here for Full Prescribing Information.
Do you wish to leave this site?